CCS
GEVA

Crosspoint Capital Strategies’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Crosspoint Capital Strategies’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-100
Closed -$10K – 685
2013
Q4 		$10K Buy
+100
New +$5.93K ﹤0.01% 437

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Crosspoint Capital Strategies's GEVA Position: Q1 2014 in Review

Crosspoint Capital Strategies sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2014, closing a stake of 100 shares — an estimated $10K sold.

Crosspoint Capital Strategies first reported a position in GEVA in Q4 2013 and held it in 1 quarter. The position peaked at $10K in Q4 2013. 115 funds tracked by Wall St. Rank hold GEVA as of Q1 2014.

  • Crosspoint Capital Strategies reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 100 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2014, an estimated $10K.
  • Crosspoint Capital Strategies first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 1 quarter.
  • Crosspoint Capital Strategies's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $10K in Q4 2013.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2014, filed 23 Apr 2014.